Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, ADMA BIOLOGICS, INC. reported revenue of $510M, up 19.6% year over year. Operating margin was 37.5% and net margin 28.8%, on a free-cash-flow margin of 5.5% with capital expenditure at 4.4% of revenue. Every figure is computed directly from ADMA's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $510M | 37.5% | 28.8% |
| FY2024 | $426M | 32.6% | 46.4% |
| FY2023 | $258M | 8.4% | -10.9% |
| FY2022 | $154M | -25.5% | -42.8% |
| FY2021 | $81M | -72.1% | -88.5% |
How does ADMA compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.